ClinicalTrials.gg

Program

larsucosterol

Also written as “DUR-928 30 mg”, “DUR-928 90 mg” and “DUR-928”.

Its studies are mostly in Hepatitis, Alcoholic · Hepatitis · Cholangitis, Sclerosing · Psoriasis, led by Bausch Health Companies.

Furthest: phase 3, since Feb 19, 20266 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies61 open or runningphase 3since Feb 19, 2026Jan 3, 2018Nov 2027phase 3 · NCT07428538

Also a collaborator on its studies: therapeutics-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 3, 2018First study: phase 2 study in Cholangitis, SclerosingFirst studyNCT03394781 · 5 enrolled · United States
  2. Feb 1, 2018Phase 2 study in Hepatitis, AlcoholicNCT03432260 · 19 enrolled · United States
  3. Feb 5, 2019Phase 2 study in Plaque PsoriasisNCT03837743 · 25 enrolled · United States
  4. Jun 23, 2020Phase 2 study in SARS-CoV-2NCT04447404 · 2 enrolled · United States
  5. Sep 18, 2020Phase 2 study in Hepatitis, AlcoholicNCT04563026 · 307 enrolled · United States, Australia, Austria and more
  6. Feb 19, 2026Phase 3 study in HepatitisPhase 3 reachedNCT07428538 · 350 planned · United States

Ahead

  1. Nov 2027Primary completion: phase 3 study in HepatitisNCT07428538

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07428538Hepatitis · United States3RecruitingNov 2027350
NCT04563026Hepatitis, Alcoholic · United States, Australia, Austria and more2CompletedSep 6, 2023307
NCT04447404SARS-CoV-2 · United States2TerminatedMar 4, 20212
NCT03837743Plaque Psoriasis · United States2CompletedNov 11, 201925
NCT03432260Hepatitis, Alcoholic · United States2CompletedSep 9, 201919
NCT03394781Cholangitis, Sclerosing · United States2TerminatedJan 31, 20195

How it is read

Names in the registry

  • “DUR-928 30 mg”, 2 entries
  • “DUR-928 90 mg”, 2 entries
  • “DUR-928”, 2 entries
  • “Larsucosterol”, 1 entry
  • “DUR-928 150 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.